Eisai Predicts "Mayhem" For Kisplyx After NICE Finally Okays Halaven
On the basis of its experience with Halaven, Eisai is predicting that its kidney cancer drug Kisplyx will face a difficult journey getting the OK from NICE, England's health technology appraisal institute.
